We use cookies and the web analytics service Matomo to customize this website to your needs. Your visit is currently not being tracked.
If you would like to help us, you can choose to allow your visit to be anonymously counted. Your decision will be stored in a consent cookie that is automatically deleted after 24 hours. No data is shared with third parties. For more information, please refer to our data protection. Information about our service providers can be found in the imprint.
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
